Identification | Back Directory | [Name]
2-Pyrimidinamine, 5-chloro-N-[5-chloro-2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-4-[1-(ethylsulfonyl)-1H-indol-3-yl]- | [CAS]
2433837-65-9 | [Synonyms]
2-Pyrimidinamine, 5-chloro-N-[5-chloro-2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-4-[1-(ethylsulfonyl)-1H-indol-3-yl]- | [Molecular Formula]
C31H37Cl2N7O3S | [MOL File]
2433837-65-9.mol | [Molecular Weight]
658.64 |
Chemical Properties | Back Directory | [Boiling point ]
832.1±75.0 °C(Predicted) | [density ]
1.43±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 12.5 mg/mL (18.98 mM; ultrasonic and warming and heat to 80°C) | [form ]
Solid | [pka]
8.14±0.42(Predicted) | [color ]
Light yellow to yellow |
Hazard Information | Back Directory | [Uses]
EGFR-IN-69 (compound 17g) is a potent EGFR inhibitor, with IC50 values of 4.3, 6.6 and 25.6 nM against EGFRL858R/T790M/C797S, EGFRL858R/T790M, and EGFR19del/T790M/C797S, respectively. EGFR-IN-69 can be used for non-small-cell-lung-cancer (NSCLC) research[1]. | [IC 50]
EGFR L858R/T790M/C797S: 4.3 ± 0.9 nM (IC50); EGFRL858R/T790M: 6.6 ± 0.8 nM (IC50); EGFRdel19 T790M C797S: 25.6 ± 7.5 nM (IC50); EGFRWT: 816.0 ± 82 nM (IC50) | [storage]
Store at -20°C | [References]
[1] Chen H, et al. Conformational Constrained 4-(1-Sulfonyl-3-indol)yl-2-phenylaminopyrimidine Derivatives as New Fourth-Generation Epidermal Growth Factor Receptor Inhibitors Targeting T790M/C797S Mutations. J Med Chem. 2022 May 12;65(9):6840-6858. DOI:10.1021/acs.jmedchem.2c00168 |
|
|